CLINICAL_TRIALS
trial_result
· 2017-03-15
Clinical Trial Update: Study of ARQ 197 Monotherapy [Phase 2]
Summary
This update covers a completed Phase 2 study of tivantinib (ARQ 197) as monotherapy for gastric cancer sponsored by Kyowa Kirin.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED